You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEntacapone
Accession NumberDB00494  (APRD00416)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor.
Structure
Thumb
Synonyms
(e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
Comtan
Comtess
Entacapona
Entacapone
Entacaponum
N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
External Identifiers
  • OR 611
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-entacaponetablet200 mgoralAuro Pharma IncNot applicableNot applicableCanada
Comtantablet, film coated200 mg/1oralCardinal Health2000-01-01Not applicableUs
Comtantablet, film coated200 mg/1oralNovartis Pharmaceuticals Corporation1999-10-19Not applicableUs
ComtanFilm-coated tablet200 mgOral useNovartis Europharm Limited1998-09-22Not applicableEu
ComtanFilm-coated tablet200 mgOral useNovartis Europharm Limited1998-09-22Not applicableEu
Comtantablet200 mgoralNovartis Pharmaceuticals Canada Inc2001-06-21Not applicableCanada
ComtanFilm-coated tablet200 mgOral useNovartis Europharm Limited1998-09-22Not applicableEu
ComtessFilm-coated tablet200 mgOral useOrion Corporation1998-09-16Not applicableEu
ComtessFilm-coated tablet200 mgOral useOrion Corporation1998-09-16Not applicableEu
ComtessFilm-coated tablet200 mgOral useOrion Corporation1998-09-16Not applicableEu
ComtessFilm-coated tablet200 mgOral useOrion Corporation1998-09-16Not applicableEu
Entacaponetablet, film coated200 mg/1oralWockhardt USA LLC.2012-09-30Not applicableUs
Entacaponetablet, film coated200 mg/1oralAv Kare, Inc.2014-06-20Not applicableUs
Entacaponetablet, film coated200 mg/1oralWockhardt Limited2012-09-30Not applicableUs
Entacaponetablet, film coated200 mg/1oralKAISER FOUNDATION HOSPITALS2014-10-10Not applicableUs
Entacaponetablet, film coated200 mg/1oralAvera Mc Kennan Hospital2015-09-23Not applicableUs
Entacaponetablet, film coated200 mg/1oralSun Pharma Global FZE2013-04-01Not applicableUs
Entacaponetablet, film coated200 mg/1oralWockhardt Limited2012-09-30Not applicableUs
Entacaponetablet, film coated200 mg/1oralMylan Pharmaceuticals Inc.2013-06-26Not applicableUs
Entacaponetablet, film coated200 mg/1oralMylan Institutional Inc.2013-12-12Not applicableUs
Entacaponetablet, film coated200 mg/1oralWockhardt USA LLC.2012-09-30Not applicableUs
Entacaponetablet, film coated200 mg/1oralSandoz Inc2014-06-04Not applicableUs
Entacapone OrionFilm-coated tablet200 mgOral useOrion Corporation2011-08-18Not applicableEu
Entacapone OrionFilm-coated tablet200 mgOral useOrion Corporation2011-08-18Not applicableEu
Entacapone OrionFilm-coated tablet 1200 mgOral useOrion Corporation2011-08-18Not applicableEu
Entacapone OrionFilm-coated tablet200 mgOral useOrion Corporation2011-08-18Not applicableEu
Mylan-entacaponetablet200 mgoralMylan Pharmaceuticals Ulc2012-07-31Not applicableCanada
Sandoz Entacaponetablet200 mgoralSandoz Canada Incorporated2012-03-30Not applicableCanada
Teva-entacaponetablet200 mgoralTeva Canada Limited2012-03-29Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-entacaponetablet200 mgoralApotex IncNot applicableNot applicableCanada
Entacaponetablet, film coated200 mg/1oralSun Pharma Global FZE2012-07-18Not applicableUs
Entacaponetablet, film coated200 mg/1oralAmerican Health Packaging2016-02-01Not applicableUs
Entacaponetablet, film coated200 mg/1oralWockhardt Limited2012-08-16Not applicableUs
Entacaponetablet, film coated200 mg/1oralAurobindo Pharma Limited2015-06-19Not applicableUs
Entacaponetablet, film coated200 mg/1oralWockhardt USA LLC.2012-08-16Not applicableUs
Entacapone TevaFilm-coated tablet200 mgOral useTeva Pharma B.V.2011-02-18Not applicableEu
Entacapone TevaFilm-coated tablet200 mgOral useTeva Pharma B.V.2011-02-18Not applicableEu
Entacapone TevaFilm-coated tablet200 mgOral useTeva Pharma B.V.2011-02-18Not applicableEu
Entacapone TevaFilm-coated tablet200 mgOral useTeva Pharma B.V.2011-02-18Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnxoponeRoot
ComtadeNovartis
ComtessOrion
Brand mixtures
NameLabellerIngredients
Carbidopa, Levodopa and EntacaponeMylan Pharmaceuticals Inc.
Carbidopa, Levodopa, and EntacaponeSandoz Inc
StalevoNovartis Pharmaceuticals Corporation
SaltsNot Available
Categories
UNII4975G9NM6T
CAS number130929-57-6
WeightAverage: 305.286
Monoisotopic: 305.101170605
Chemical FormulaC14H15N3O5
InChI KeyInChIKey=JRURYQJSLYLRLN-BJMVGYQFSA-N
InChI
InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
IUPAC Name
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
SMILES
CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydroxycinnamic acids and derivatives. These are compounds containing an cinnamic acid (or a derivative thereof) where the benzene ring is hydroxylated.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassCinnamic acids and derivatives
Sub ClassHydroxycinnamic acids and derivatives
Direct ParentHydroxycinnamic acids and derivatives
Alternative Parents
Substituents
  • Hydroxycinnamic acid or derivatives
  • Nitrophenol derivative
  • Phenylpropene
  • Nitrobenzene
  • 1,2-diphenol
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Organic nitro compound
  • Tertiary amine
  • Organic nitrite
  • C-nitro compound
  • Carboxamide group
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Nitrile
  • Carbonitrile
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".
PharmacodynamicsEntacapone is structurally and pharmacologically related to tolcapone, but unlike tolcapone, is not associated with hepatotoxicity. Entacapone is used in the treatment of Parkinson’s disease as an adjunct to levodopa/carbidopa therapy. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). In mammals, COMT is distributed throughout various organs with the highest activities in the liver and kidney. COMT also occurs in the heart, lung, smooth and skeletal muscles, intestinal tract, reproductive organs, various glands, adipose tissue, skin, blood cells and neuronal tissues, especially in glial cells. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa, catalyzing the it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery.
Mechanism of actionThe mechanism of action of entacapone is believed to be through its ability to inhibit COMT in peripheral tissues, altering the plasma pharmacokinetics of levodopa. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to a greater reduction in the manifestations of parkinsonian syndrome.
Related Articles
AbsorptionEntacapone is rapidly absorbed (approximately 1 hour). The absolute bioavailability following oral administration is 35%.
Volume of distribution
  • 20 L
Protein binding98% (bind to serum albumin)
Metabolism

Metabolized via isomerization to the cis-isomer, followed by direct glucuronidation of the parent and cis-isomer.

Route of eliminationEntacapone is almost completely metabolized prior to excretion, with only a very small amount (0.2% of dose) found unchanged in urine. As only about 10% of the entacapone dose is excreted in urine as parent compound and conjugated glucuronide, biliary excretion appears to be the major route of excretion of this drug.
Half life0.4-0.7 hour
Clearance
  • 850 mL/min
ToxicitySide effect include increase the occurrence of orthostatic hypotension, severe rhabdomyolysis, dyskinesia, hallucinations, hyperkinesia, hypokinesia, dizziness, fatigu,e gastrointestinal effects including abdominal pain constipation diarrhea nausea
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9185
Blood Brain Barrier-0.9104
Caco-2 permeable-0.5817
P-glycoprotein substrateSubstrate0.64
P-glycoprotein inhibitor INon-inhibitor0.7342
P-glycoprotein inhibitor IINon-inhibitor0.8442
Renal organic cation transporterNon-inhibitor0.9311
CYP450 2C9 substrateNon-substrate0.8406
CYP450 2D6 substrateNon-substrate0.8932
CYP450 3A4 substrateNon-substrate0.5057
CYP450 1A2 substrateNon-inhibitor0.7003
CYP450 2C9 inhibitorNon-inhibitor0.581
CYP450 2D6 inhibitorNon-inhibitor0.8548
CYP450 2C19 inhibitorNon-inhibitor0.6098
CYP450 3A4 inhibitorNon-inhibitor0.5133
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7901
Ames testAMES toxic0.5803
CarcinogenicityNon-carcinogens0.561
BiodegradationNot ready biodegradable0.9457
Rat acute toxicity2.6750 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8608
hERG inhibition (predictor II)Non-inhibitor0.8332
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Orion corp
Packagers
Dosage forms
FormRouteStrength
Film-coated tabletOral use200 mg
Tabletoral200 mg
Tablet, film coatedoral200 mg/1
Film-coated tablet 1Oral use200 mg
Tabletoral
Tablet, film coatedoral
Prices
Unit descriptionCostUnit
Comtan 200 mg tablet2.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1334967 No1995-03-282012-03-28Canada
CA2342634 No2008-01-292019-09-13Canada
US5135950 No1993-10-312010-10-31Us
US6500867 No2000-06-292020-06-29Us
US6599530 No1998-09-142018-09-14Us
US6797732 No2000-06-292020-06-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0797 mg/mLALOGPS
logP2.5ALOGPS
logP1.63ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)5.68ChemAxon
pKa (Strongest Basic)-0.036ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area130.38 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity80.51 m3·mol-1ChemAxon
Polarizability29.48 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Pandurang Deshpande, Parven Luthra, Anand Pandey, Dharmesh Dhameliya, “Process for the preparation of (E)-2-cyano-3-(3, 4-dihydroxy-5-nitrophenyl)-N, N-diethyl-2-propenamide (entacapone).” U.S. Patent US20060258877, issued November 16, 2006.

US20060258877
General References
  1. Najib J: Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. [PubMed:11440283 ]
  2. Chong BS, Mersfelder TL: Entacapone. Ann Pharmacother. 2000 Sep;34(9):1056-65. [PubMed:10981253 ]
  3. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. [PubMed:11939936 ]
  4. Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9. [PubMed:12876237 ]
  5. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800 ]
  6. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160 ]
External Links
ATC CodesN04BX02
AHFS Codes
  • 28:92.00
PDB EntriesNot Available
FDA labelDownload (52.6 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Entacapone.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Entacapone is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Entacapone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Entacapone.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Entacapone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Entacapone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Entacapone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Entacapone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Entacapone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Entacapone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Entacapone.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Entacapone.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Entacapone.
AmoxapineThe risk or severity of adverse effects can be increased when Entacapone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Entacapone.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Entacapone.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Entacapone.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Entacapone.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Entacapone.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Entacapone.
AzelastineEntacapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Entacapone.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Entacapone.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Entacapone.
BenmoxinThe risk or severity of adverse effects can be increased when Entacapone is combined with Benmoxin.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Entacapone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Entacapone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Entacapone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
BrimonidineThe risk or severity of adverse effects can be increased when Entacapone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Entacapone.
BrompheniramineThe risk or severity of adverse effects can be increased when Entacapone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Entacapone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Entacapone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Entacapone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Entacapone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Entacapone.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Entacapone.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Entacapone.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Entacapone.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Entacapone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Entacapone.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Entacapone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Entacapone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Entacapone.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Entacapone.
CaroxazoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Caroxazone.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Entacapone.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Entacapone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Entacapone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Entacapone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Entacapone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Entacapone is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Entacapone.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Entacapone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Entacapone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Entacapone.
CitalopramThe risk or severity of adverse effects can be increased when Entacapone is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Entacapone.
ClidiniumThe risk or severity of adverse effects can be increased when Entacapone is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Entacapone.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Entacapone.
ClomipramineThe risk or severity of adverse effects can be increased when Entacapone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Entacapone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Entacapone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Entacapone.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Entacapone.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Entacapone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Entacapone.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Entacapone.
CyclizineThe risk or severity of adverse effects can be increased when Entacapone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Entacapone.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Entacapone.
DantroleneThe risk or severity of adverse effects can be increased when Entacapone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Entacapone.
DapoxetineThe risk or severity of adverse effects can be increased when Entacapone is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Entacapone.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Entacapone.
DesipramineThe risk or severity of adverse effects can be increased when Entacapone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Entacapone is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Entacapone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Entacapone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Entacapone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Entacapone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Entacapone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Entacapone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Entacapone.
DiethylstilbestrolThe metabolism of Diethylstilbestrol can be decreased when combined with Entacapone.
DifenoxinThe risk or severity of adverse effects can be increased when Entacapone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Entacapone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Entacapone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Entacapone.
DimenhydrinateThe risk or severity of adverse effects can be increased when Entacapone is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Entacapone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Entacapone.
DobutamineThe metabolism of Dobutamine can be decreased when combined with Entacapone.
DopamineThe metabolism of Dopamine can be decreased when combined with Entacapone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Entacapone.
DoxepinThe risk or severity of adverse effects can be increased when Entacapone is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
DoxylamineThe risk or severity of adverse effects can be increased when Entacapone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Entacapone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Entacapone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Entacapone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Entacapone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Entacapone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Entacapone.
EfavirenzThe risk or severity of adverse effects can be increased when Entacapone is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Entacapone is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Entacapone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Entacapone.
EthanolEntacapone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Entacapone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Entacapone.
EthosuximideThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Entacapone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Entacapone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Entacapone.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Entacapone.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Entacapone.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Entacapone.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Entacapone.
EtoperidoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Entacapone.
EzogabineThe risk or severity of adverse effects can be increased when Entacapone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Entacapone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Entacapone.
FenfluramineThe risk or severity of adverse effects can be increased when Entacapone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Entacapone.
FexofenadineThe risk or severity of adverse effects can be increased when Entacapone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Entacapone is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Entacapone.
FlunarizineThe risk or severity of adverse effects can be increased when Entacapone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Entacapone.
FluoxetineThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Entacapone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Entacapone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Entacapone.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Entacapone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Entacapone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Entacapone.
FurazolidoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Furazolidone.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Entacapone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Entacapone is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Entacapone.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Entacapone.
GuanfacineThe risk or severity of adverse effects can be increased when Entacapone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Entacapone.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Entacapone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Entacapone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Entacapone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Entacapone.
HydracarbazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Hydracarbazine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Entacapone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Entacapone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
HydroxyzineThe risk or severity of adverse effects can be increased when Entacapone is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Entacapone.
IndalpineThe risk or severity of adverse effects can be increased when Entacapone is combined with Indalpine.
IproclozideThe risk or severity of adverse effects can be increased when Entacapone is combined with Iproclozide.
IproniazidThe risk or severity of adverse effects can be increased when Entacapone is combined with Iproniazid.
IsocarboxazidThe risk or severity of adverse effects can be increased when Entacapone is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Entacapone.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Entacapone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Entacapone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Entacapone.
LamotrigineThe risk or severity of adverse effects can be increased when Entacapone is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Entacapone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Entacapone.
LevocabastineThe risk or severity of adverse effects can be increased when Entacapone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Entacapone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Entacapone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Entacapone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Entacapone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Entacapone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Entacapone.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Entacapone.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Entacapone.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Entacapone.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Entacapone.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Entacapone.
Lu AA21004The risk or severity of adverse effects can be increased when Entacapone is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Entacapone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Entacapone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Entacapone is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Mebanazine.
MeclizineThe risk or severity of adverse effects can be increased when Entacapone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Entacapone.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Entacapone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Entacapone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Entacapone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Entacapone.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Entacapone.
MetaxaloneThe risk or severity of adverse effects can be increased when Entacapone is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Entacapone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Entacapone.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Entacapone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Entacapone.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Entacapone.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Entacapone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Entacapone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Entacapone.
MethsuximideThe risk or severity of adverse effects can be increased when Entacapone is combined with Methsuximide.
MethyldopaThe metabolism of Methyldopa can be decreased when combined with Entacapone.
Methylene blueThe risk or severity of adverse effects can be increased when Entacapone is combined with Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Entacapone.
MetyrosineEntacapone may increase the sedative activities of Metyrosine.
MicafunginThe metabolism of Micafungin can be decreased when combined with Entacapone.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Entacapone.
MilnacipranThe risk or severity of adverse effects can be increased when Entacapone is combined with Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Entacapone is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
MirtazapineEntacapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Entacapone.
MoclobemideThe risk or severity of adverse effects can be increased when Entacapone is combined with Moclobemide.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Entacapone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Entacapone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
NabiloneThe risk or severity of adverse effects can be increased when Entacapone is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Entacapone.
NialamideThe risk or severity of adverse effects can be increased when Entacapone is combined with Nialamide.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Entacapone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Entacapone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Entacapone.
NortriptylineThe risk or severity of adverse effects can be increased when Entacapone is combined with Nortriptyline.
OctamoxinThe risk or severity of adverse effects can be increased when Entacapone is combined with Octamoxin.
OlanzapineThe risk or severity of adverse effects can be increased when Entacapone is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Entacapone is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Entacapone.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Entacapone.
OrphenadrineEntacapone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Entacapone.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Entacapone.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Entacapone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Entacapone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Entacapone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Entacapone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Entacapone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Entacapone.
ParaldehydeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Entacapone.
PargylineThe risk or severity of adverse effects can be increased when Entacapone is combined with Pargyline.
ParoxetineThe risk or severity of adverse effects can be increased when Entacapone is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Entacapone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Entacapone.
PerampanelThe risk or severity of adverse effects can be increased when Entacapone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Entacapone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Entacapone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Entacapone.
PhenelzineThe risk or severity of adverse effects can be increased when Entacapone is combined with Phenelzine.
PheniprazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Pheniprazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Entacapone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Entacapone.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Phenoxypropazine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Entacapone.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Entacapone.
PipamperoneThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Entacapone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Entacapone.
PipotiazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Pipotiazine.
PirlindoleThe risk or severity of adverse effects can be increased when Entacapone is combined with Pirlindole.
PivhydrazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Entacapone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Entacapone is combined with Pomalidomide.
PramipexoleEntacapone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Entacapone.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Entacapone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Entacapone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Entacapone.
PrimidoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Entacapone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Entacapone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Entacapone.
PromethazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Entacapone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Entacapone.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Entacapone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Entacapone.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Entacapone.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Entacapone.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Entacapone.
RamelteonThe risk or severity of adverse effects can be increased when Entacapone is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Entacapone is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Entacapone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Entacapone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Entacapone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Entacapone.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Entacapone.
RopiniroleEntacapone may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Entacapone.
RotigotineEntacapone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Entacapone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Entacapone.
SafrazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Safrazine.
ScopolamineThe risk or severity of adverse effects can be increased when Entacapone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Entacapone.
SelegilineThe risk or severity of adverse effects can be increased when Entacapone is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Entacapone.
SertralineThe risk or severity of adverse effects can be increased when Entacapone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Entacapone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Entacapone.
StiripentolThe risk or severity of adverse effects can be increased when Entacapone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Entacapone.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Entacapone.
SuvorexantThe risk or severity of adverse effects can be increased when Entacapone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Entacapone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Entacapone is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Entacapone.
TetrabenazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Entacapone.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Entacapone.
ThalidomideEntacapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Entacapone.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Entacapone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Entacapone.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Entacapone.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Entacapone.
TiagabineThe risk or severity of adverse effects can be increased when Entacapone is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Entacapone.
TizanidineThe risk or severity of adverse effects can be increased when Entacapone is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Entacapone.
ToloxatoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Toloxatone.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Entacapone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Entacapone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Entacapone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Entacapone.
TrazodoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Entacapone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Entacapone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Entacapone.
TrimipramineThe risk or severity of adverse effects can be increased when Entacapone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Entacapone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Entacapone.
VigabatrinThe risk or severity of adverse effects can be increased when Entacapone is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Entacapone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Entacapone.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Entacapone.
ZiconotideThe risk or severity of adverse effects can be increased when Entacapone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Entacapone is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Entacapone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Entacapone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Entacapone.
ZonisamideThe risk or severity of adverse effects can be increased when Entacapone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Entacapone.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Entacapone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Entacapone.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Najib J: Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. [PubMed:11440283 ]
  3. Chong BS, Mersfelder TL: Entacapone. Ann Pharmacother. 2000 Sep;34(9):1056-65. [PubMed:10981253 ]
  4. Holm KJ, Spencer CM: Entacapone. A review of its use in Parkinson's disease. Drugs. 1999 Jul;58(1):159-77. [PubMed:10439935 ]
  5. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. [PubMed:11939936 ]
  6. Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9. [PubMed:12876237 ]
  7. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800 ]
  8. Tai CH, Wu RM: Catechol-O-methyltransferase and Parkinson's disease. Acta Med Okayama. 2002 Feb;56(1):1-6. [PubMed:11873938 ]
  9. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160 ]
  10. Ruottinen HM, Rinne UK: COMT inhibition in the treatment of Parkinson's disease. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. [PubMed:9808337 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Lautala P, Ethell BT, Taskinen J, Burchell B: The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2000 Nov;28(11):1385-9. [PubMed:11038168 ]
  2. Kurkela M, Garcia-Horsman JA, Luukkanen L, Morsky S, Taskinen J, Baumann M, Kostiainen R, Hirvonen J, Finel M: Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J Biol Chem. 2003 Feb 7;278(6):3536-44. Epub 2002 Nov 14. [PubMed:12435745 ]
  3. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, Finel M: Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2005 Jul;33(7):1017-26. Epub 2005 Mar 31. [PubMed:15802387 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 02:26